Loading...
XSTOSTIL
Market cap167mUSD
Dec 23, Last price  
207.00SEK
1D
6.15%
1Q
-0.48%
Jan 2017
351.97%
Name

Stille AB

Chart & Performance

D1W1MN
XSTO:STIL chart
P/E
69.80
P/S
6.31
EPS
2.97
Div Yield, %
0.49%
Shrs. gr., 5y
0.80%
Rev. gr., 5y
16.78%
Revenues
295m
+19.70%
96,611,000100,818,00083,411,00089,909,00088,044,00089,095,00081,467,00083,479,00096,334,000121,818,000135,796,000156,673,000142,627,000187,087,000246,350,000294,893,000
Net income
27m
-2.48%
-1,773,0005,275,0003,485,000-1,053,000-1,916,0003,288,0001,890,00010,496,00016,789,00014,193,00020,179,00022,879,0008,273,00016,097,00027,324,00026,646,000
CFO
37m
+16.72%
3,257,000-797,0001,414,0001,079,0006,984,000-1,725,000-1,351,00010,749,00019,414,00018,946,00013,452,00025,811,00020,556,0007,278,00031,936,00037,277,000
Dividend
May 08, 20231.8 SEK/sh
Earnings
Feb 13, 2025

Profile

Stille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.
URL
https://www.stille.se/
IPO date
Aug 29, 1997
Employees
103
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
294,893
19.70%
246,350
31.68%
187,087
31.17%
Cost of revenue
252,400
216,722
164,709
Unusual Expense (Income)
NOPBT
42,493
29,628
22,378
NOPBT Margin
14.41%
12.03%
11.96%
Operating Taxes
4,939
5,479
4,522
Tax Rate
11.62%
18.49%
20.21%
NOPAT
37,554
24,149
17,856
Net income
26,646
-2.48%
27,324
69.75%
16,097
94.57%
Dividends
(9,024)
(5,013)
(8,207)
Dividend yield
1.19%
0.89%
1.09%
Proceeds from repurchase of equity
205,000
BB yield
-27.05%
Debt
Debt current
24,876
12,966
13,210
Long-term debt
65,224
83,404
95,883
Deferred revenue
2,673
Other long-term liabilities
37,008
32,214
29,073
Net debt
(151,346)
59,693
81,298
Cash flow
Cash from operating activities
37,277
31,936
7,278
CAPEX
(1,408)
(8,042)
(19,022)
Cash from investing activities
(12,903)
(8,042)
(51,896)
Cash from financing activities
178,993
(18,539)
33,217
FCF
(187,011)
14,289
(34,572)
Balance
Cash
241,446
36,677
27,795
Long term investments
Excess cash
226,701
24,360
18,441
Stockholders' equity
149,900
121,681
79,970
Invested Capital
582,304
266,830
242,336
ROIC
8.85%
9.49%
10.36%
ROCE
5.67%
9.56%
8.05%
EV
Common stock shares outstanding
5,018
5,013
5,013
Price
151.00
34.82%
112.00
-25.58%
150.50
63.59%
Market cap
757,730
34.94%
561,510
-25.58%
754,529
69.88%
EV
606,384
621,203
835,827
EBITDA
56,850
39,274
29,132
EV/EBITDA
10.67
15.82
28.69
Interest
10,099
2,336
1,521
Interest/NOPBT
23.77%
7.88%
6.80%